News Daily News SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide Michael O'Riordan December 18, 2025
News Conference News AHA 2025 Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV Michael O'Riordan November 08, 2025
News Opinion CV Team Dispatch September 2025 Dispatch for the CV Team L.A. McKeown September 30, 2025
News Daily News CVD Still the Leading Cause of Death and Disease Globally Michael O'Riordan September 24, 2025
News Daily News Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions L.A. McKeown September 22, 2025
News Conference News ESC 2025 High hs-CRP Linked to More CVD Events in Women Lacking Traditional Risk Factors Caitlin E. Cox August 29, 2025
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for July 2025 Caitlin E. Cox July 31, 2025
News Conference News SCCT 2025 AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry Yael L. Maxwell July 21, 2025
News Daily News Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050 Todd Neale July 16, 2025
News Conference News EuroPCR 2025 Higher Mortality With TAVI Over Surgery in Bicuspid Aortic Stenosis Michael O'Riordan May 22, 2025
News Daily News Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE Caitlin E. Cox April 23, 2025
News Daily News Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI Michael O'Riordan April 22, 2025
News Daily News High-Sensitivity Troponin Tests Might Aid in Primary Prevention Yael L. Maxwell April 16, 2025
News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
News Daily News Danish Analysis Updates Stroke and MI Risks of Contemporary Contraceptives L.A. McKeown March 03, 2025
News Daily News Use of Secondary CVD Prevention Meds Still Meager Worldwide Caitlin E. Cox February 03, 2025
News Daily News Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations L.A. McKeown January 31, 2025